The MHCRC is intended to foster high-quality, interdisciplinary research in schizophrenia, facilitate research training, and promote the development of young investigators. In addition, it is intended to serve as a national resource in the dissemination information, training and consultation, as well as the conduct of collaborative studies and the sharing of data. The major theme of the center is to improve outcome in schizophrenia and to further understanding of heterogeneity in phenomology, coarse and treatment response. The research conducted by the CRC brings to bear a variety of perspectives with clinical psychopharmacologic response as an important """"""""cutting edge,"""""""" and the novel or atypical clinical and biologic effects of new antipsychotics as an increasingly important focus. The combination of large-scale, cross-sectional and longitudinal, clinical and biologic assessments in the context of controlled treatment has been a major goal. The CRC consists of four core units: administrative, clinical assessment and training, study management and biostatistics; as well as two specialty units: clinical psychopharmacology, neuroimaging. Our program is organized to take full advantage of an outstanding stable and cooperative clinical population and excellent clinical facilities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH041960-13
Application #
2858008
Study Section
Clinical Centers and Special Projects Review Committee (CCSP)
Program Officer
Lebowitz, Barry D
Project Start
1986-09-25
Project End
1999-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
13
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
Sevy, Serge; Robinson, Delbert G; Sunday, Suzanne et al. (2011) Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res 188:310-4
Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J et al. (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36:1738-46
Sevy, Serge; Robinson, Delbert G; Napolitano, Barbara et al. (2010) Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr Res 120:101-7
Miller, Rachel; Ream, Geoffrey; McCormack, Joanne et al. (2009) A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 113:138-44
Goldberg, Terry E; Burdick, Katherine E; McCormack, Joanne et al. (2009) Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr Res 107:262-6
Javitt, D C; Shelley, A M; Silipo, G et al. (2000) Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry 57:1131-7